1. Home
  2. CLLS vs AKBA Comparison

CLLS vs AKBA Comparison

Compare CLLS & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cellectis S.A.

CLLS

Cellectis S.A.

SELL

Current Price

$0.97

Market Cap

103.8M

Sector

Health Care

ML Signal

SELL

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

N/A

Current Price

$0.39

Market Cap

107.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CLLS
AKBA
Founded
1999
2007
Country
France
United States
Employees
N/A
194
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
103.8M
107.0M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
CLLS
AKBA
Price
$0.97
$0.39
Analyst Decision
Buy
Buy
Analyst Count
5
6
Target Price
★ $4.45
$2.67
AVG Volume (30 Days)
55.6K
★ 7.4M
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 93.94
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$0.36
52 Week High
$5.45
$1.73

Technical Indicators

Market Signals
Indicator
CLLS
AKBA
Relative Strength Index (RSI) 37.12 33.07
Support Level N/A $0.36
Resistance Level $1.28 $1.00
Average True Range (ATR) 0.12 0.07
MACD 0.00 -0.01
Stochastic Oscillator 0.00 6.68

Price Performance

Historical Comparison
CLLS
AKBA

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: